Vertex Pharmaceuticals, Inc (VRTX) concluded trading on Thursday at a closing price of $396.64, with 8.2 million shares of worth about $3.25 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.38% during that period and on December 19, 2024 the price saw a loss of about -11.37%. Currently the company’s common shares owned by public are about 257.74M shares, out of which, 256.90M shares are available for trading.
Stock saw a price change of -14.54% in past 5 days and over the past one month there was a price change of -11.47%. Year-to-date (YTD), VRTX shares are showing a performance of -2.52% which decreased to -1.61% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $391.01 but also hit the highest price of $519.88 during that period. The average intraday trading volume for Vertex Pharmaceuticals, Inc shares is 1.19 million. The stock is currently trading -13.70% below its 20-day simple moving average (SMA20), while that difference is down -16.03% for SMA50 and it goes to -13.34% lower than SMA200.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) currently have 257.74M outstanding shares and institutions hold larger chunk of about 92.75% of that.
The stock has a current market capitalization of $102.15B and its 3Y-monthly beta is at 0.38. It has posted earnings per share of -$1.99 in the same period. It has Quick Ratio of 2.20 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VRTX, volatility over the week remained 3.53% while standing at 2.43% over the month.
Stock’s fiscal year EPS is expected to drop by -96.45% while it is estimated to increase by 3389.29% in next year. EPS is likely to grow at an annualized rate of 12.20% for next 5-years, compared to annual growth of 11.42% made by the stock over the past 5-years.
Coverage by Jefferies stated Vertex Pharmaceuticals, Inc (VRTX) stock as a Buy in their note to investors on December 09, 2024, suggesting a price target of $550 for the stock. Stock get a Mkt perform rating from Raymond James on October 10, 2024.
